Searched for
CORONA REMEDIES FINANCIALS
Dividends and bonus issues: 31 stocks turning ex-record date this week. Do you own any?As many as 31 companies, including HDFC Bank, Tata group firms and Brigade Enterprises, will turn ex-record date for dividends and bonus is...- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian markets closed lower amid selling in financial, consumer and realty stocks, with Nifty and Sensex declining. Technical indicators si...
- Corona Remedies shares climb 3% after blockbuster debut. What’s driving the post-listing surge?Corona Remedies shares rose sharply on December 15, extending gains after a blockbuster IPO debut. Strong institutional demand, consistent ...
- Corona Remedies shares make strong start, list at 38% premium over IPO priceCorona Remedies Share Price: Corona Remedies debuted on Dalal Street with a significant 38.42% premium, opening at Rs 1,470 on NSE and Rs 1...
- IPO Calendar next week: 4 new issues, ICICI Prudential AMC among 15 listings on investors radarIndia's primary market is buzzing with activity as four new public issues, totaling Rs 830 crore, are set to launch, led by KSH Internation...
- How to check Corona Remedies IPO allotment on Bigshare Services as GMP stays strongCorona Remedies’ Rs 655-crore offer-for-sale IPO saw strong demand across investor categories, with overall subscription at 144.54 times an...
- Corona Remedies IPO Day 3: Issue subscribed over 18.5x, GMP at 25%. Should you apply?Corona Remedies' Rs 655.37-crore IPO is in its final subscription day. Investors show strong interest, with the issue subscribed 18.54 time...
- Corona Remedies IPO Day 2: Nearly 3x subscription so far; check GMP trends & should you apply?Corona Remedies’ Rs 655-crore IPO entered Day 2 after achieving 62% subscription on Day 1, driven largely by retail demand. The IPO’s grey ...
- Corona Remedies IPO Day 1: Registers over 30% subscription, strong GMP, and key detailsCorona Remedies’ IPO opened with decent subscription demand, led by strong retail demand and a robust Rs 290 grey-market premium. The Rs 65...
- Corona Remedies IPO: Check GMP, price band, review, subscription and other detailsCorona Remedies' IPO is now open for subscription. The company is offering shares at a price band of Rs 1,008 to Rs 1,062. The issue aims t...
- Is Corona Remedies’ IPO a compelling bet for long-term wealth creation?Corona Remedies is set to raise ₹655.4 crore via an offer for sale. The company focuses on specialist doctors, driving faster revenue growt...
- Corona Remedies IPO opens next week: GMP among 10 things to know before subscriptionCorona Remedies is launching its Rs 655 crore IPO next week. The Gujarat-based pharmaceutical firm is offering 100% of its shares. The grey...
- Pharma firm Corona Remedies IPO to open on Dec 8; sets price band at Rs 1,008-1,062/ sharePharma firm Corona Remedies, backed by ChrysCapital, has set its IPO price band at Rs 1,008-1,062, valuing the company at nearly Rs 6,500 c...
- Corona Remedies files draft papers with Sebi for Rs 800 crore IPOCorona Remedies, an Indian pharmaceutical company, has filed preliminary documents with SEBI to launch an Rs 800-crore IPO. The IPO consist...
- Gujarat-based Trom Industries registers nearly 100% rise in sales, profit in H1Trom Industries, a Gujarat-based renewable energy company, reported increase in net sales for the first half of the fiscal year. The compan...
- Trom Industries secures Rs 33 cr orders from Gujarat Metro, Corona Remedies for solar projectsTrom Industries Ltd has secured a total of Rs 33 crore in solar project contracts, including a Rs 20.70 crore order from Gujarat Metro Rail...
- ChrysCap to buy 30% in Corona Remedies for Rs 670 croreChrysCap has signed a deal to acquire 20% stake from PE firm Creador, which is an existing investor, and another 10% from promoters, two pe...
- PE fund Creador to sell Corona Remedies stake; eyes Rs 2,400 cr valuationSpark Capital is advising the PE fund for the stake sale. The proposed deal is expected to value Corona at Rs.2000-2400 crore.
- Creador Capital close to investing Rs 118 crore for minority stake in Corona RemediesAccording to people close to the development, Creador will be picking up about 20% stake in Corona, valuing the company at around Rs 500 cr...
- Corona inks agreement with Kitozyme for a fat binder anti-obesity drugBelgium life science company, Kitozyme entered into in-licensing agreement with Corona Remedies for fat binder anti-obesity drug.
Load More
